Chengyong Wu

发表

Interactions between sirtuins and fluorogenic small-molecule substrates offer insights into inhibitor design

Kai Chen, Guo‐Bo Li, Shan Liu, 2017 .

X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells.

L. Zhong, Guo‐Bo Li, Ling-Ling Yang, 2018, European journal of medicinal chemistry.

High-resolution X-ray structure of three microtubule-stabilizing agents in complex with tubulin provide a rationale for drug design.

Bo Sun, Chengyong Wu, Yuxi Wang, 2020, Biochemical and biophysical research communications.

A Rationale for Drug Design Provided by Co-Crystal Structure of IC261 in Complex with Tubulin

Chengyong Wu, Yuxi Wang, Yiran Tao, 2021, Molecules.

The bromodomain protein BRD4 positively regulates necroptosis via modulating MLKL expression

Yuquan Wei, Shile Huang, Yiguo Hu, 2019, Cell Death & Differentiation.

Light-up RNA aptamer signaling-CRISPR-Cas13a-based mix-and-read assays for profiling viable pathogenic bacteria.

Ruijie Deng, Sha Deng, Wenhu Zhou, 2020, Biosensors & bioelectronics.

Structure-Based Development of (1-(3'-Mercaptopropanamido)methyl)boronic Acid Derived Broad-Spectrum, Dual-Action Inhibitors of Metallo- and Serine-β-Lactamases.

Q. Ma, Yong Wu, Y. Lei, 2019, Journal of medicinal chemistry.

((S)-3-Mercapto-2-methylpropanamido)acetic acid derivatives as metallo-β-lactamase inhibitors: Synthesis, kinetic and crystallographic studies.

Yongxiang Zheng, Yong Wu, Shan Liu, 2018, European journal of medicinal chemistry.

Generative deep learning enables the discovery of a potent and selective RIPK1 inhibitor

Jun Zou, Yifei Wang, Xin Yang, 2022, Nature Communications.

Molecular mechanism of crolibulin in complex with tubulin provides a rationale for drug design.

Xiaohua Jiang, Wenyue Zheng, Yang Yang, 2019, Biochemical and biophysical research communications.

Discovery and biological evaluation of 4,6-pyrimidine analogues with potential anticancer agents as novel colchicine binding site inhibitors.

Y. Liu, Jifa Zhang, Hao Chen, 2023, European journal of medicinal chemistry.

Mechanisms of spacer acquisition by sequential assembly of the adaptation module in Synechocystis

T. Fu, S. Yao, Haihuai He, 2021, Nucleic acids research.

Mechanism of microtubule stabilization by taccalonolide AJ

B. Gigant, Yamei Yu, Hao Chen, 2017, Nature Communications.

Unraveling the molecular mechanism of BNC105, a phase II clinical trial vascular disrupting agent, provides insights into drug design.

Guiping Zhang, Weimin Li, Chengyong Wu, 2020, Biochemical and biophysical research communications.

A distinct structure of Cas1-Cas2 complex provides insights into the mechanism for the longer spacer acquisition in Pyrococcus furiosus.

S. Yao, Haihuai He, Yamei Yu, 2021, International journal of biological macromolecules.

DCLK1 autoinhibition and activation in tumorigenesis

R. Thorne, A. Tong, Zhongwei Cao, 2021, Innovation.

Rh(III)-Catalyzed directed C–H carbenoid coupling reveals aromatic bisphosphonates inhibiting metallo- and Serine-β-lactamases

C. Schofield, Yong Wu, J. Brem, 2018 .

Design, Synthesis, and Biological Evaluation of Heterocyclic-Fused Pyrimidine Chemotypes Guided by X-ray Crystal Structure with Potential Antitumor and Anti-multidrug Resistance Efficacy Targeting the Colchicine Binding Site.

L. Ouyang, Xiye Wang, Yuxi Wang, 2023, Journal of medicinal chemistry.

Structure of 4'-demethylepipodophyllotoxin in complex with tubulin provides a rationale for drug design.

Xiaohua Jiang, Yamei Yu, Chengyong Wu, 2017, Biochemical and biophysical research communications.

Structure of a benzylidene derivative of 9(10H)-anthracenone in complex with tubulin provides a rationale for drug design.

Yamei Yu, Chengyong Wu, Yuxi Wang, 2018, Biochemical and biophysical research communications.

The Structure of MT189-Tubulin Complex Provides Insights into Drug Design

Wenyue Zheng, T. Meng, Yamei Yu, 2019, Letters in Drug Design & Discovery.

Discovery of Pyrrolo[3,2- d]pyrimidin-4-one Derivatives as a New Class of Potent and Cell-Active Inhibitors of P300/CBP-Associated Factor Bromodomain.

P. Brennan, Sheng-yong Yang, Luyi Huang, 2019, Journal of medicinal chemistry.

Structure-guided Discovery of a Potent and Selective Cell-active Inhibitor of SETDB1 Tudor Domain.

Sheng-yong Yang, Yinping Guo, Luyi Huang, 2021, Angewandte Chemie.

((S)-3-Mercapto-2-methylpropanamido)acetic acid derivatives as metallo-β-lactamase inhibitors: Synthesis, kinetic and crystallographic studies.

Yongxiang Zheng, Yong Wu, Shan Liu, 2018, European journal of medicinal chemistry.